Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Share

Royalty Pharma has declared a Q3 2025 dividend of $0.22 per Class A ordinary share, payable on September 10, 2025, to shareholders recorded by August 15, 2025. The company continues to demonstrate its commitment to shareholder returns, with consistent dividend payments reflecting its strong financial performance and strategic position in the biopharmaceutical sector.

Royalty Pharma plc (Nasdaq: RPRX) has announced a dividend payment for the third quarter of 2025, amounting to $0.22 per Class A ordinary share. The dividend will be distributed on September 10, 2025, to shareholders of record by August 15, 2025. This quarterly payment reflects the company's commitment to distributing a portion of its earnings to shareholders, a practice that has been consistent with its strong financial performance and strategic position in the biopharmaceutical sector.

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company has assembled a portfolio of royalties, which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation both directly and indirectly, co-funding late-stage clinical trials and new product launches in exchange for future royalties, and indirectly by acquiring existing royalties from original innovators.

The company's current portfolio includes royalties on over 35 commercial products, such as Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy. Additionally, the portfolio includes 16 development-stage product candidates, covering a wide range of therapeutic areas.

Recent strategic developments at Royalty Pharma include the completion of a major acquisition of RP LLC’s equity interests, valued at $200 million, which included the issuance of non-voting Class E ordinary shares and the assumption of a $380 million term loan facility. The company also announced significant internalization of its management structure, which is expected to generate substantial annual cash savings starting at over $100 million in 2026. Furthermore, Royalty Pharma has entered into a $2 billion funding arrangement with Revolution Medicines to support the development of daraxonrasib, a cancer drug in Phase 3 trials. These initiatives reflect the company's strategic focus on strengthening its market position and enhancing corporate governance.

For more information, visit www.royaltypharma.com.

References:
[1] https://www.morningstar.com/news/globe-newswire/9496769/royalty-pharma-declares-third-quarter-2025-dividend
[2] https://www.investing.com/news/company-news/royalty-pharma-announces-022-per-share-dividend-for-q3-2025-93CH-4141742
[3] https://www.ainvest.com/news/royalty-pharma-announces-q3-2025-dividend-0-22-share-2507/
[4] https://www.marketscreener.com/news/royalty-pharma-plc-declares-dividend-on-class-a-ordinary-share-for-third-quarter-of-2025-payable-on-ce7c5cdede8af22d
[5] https://www.stocktitan.net/news/RPRX/royalty-pharma-declares-third-quarter-2025-eiym7sqonjkp.html